"HIV-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
MeSH Number(s)
B04.820.650.589.650.350.400
B04.909.777.731.589.650.350.400
Concept/Terms
HIV-1- HIV-1
- Immunodeficiency Virus Type 1, Human
- Human Immunodeficiency Virus Type 1
- HIV-I
- Human immunodeficiency virus 1
Below are MeSH descriptors whose meaning is more general than "HIV-1".
Below are MeSH descriptors whose meaning is more specific than "HIV-1".
This graph shows the total number of publications written about "HIV-1" by people in Harvard Catalyst Profiles by year, and whether "HIV-1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 72 | 5 | 77 |
| 1994 | 84 | 8 | 92 |
| 1995 | 78 | 6 | 84 |
| 1996 | 102 | 4 | 106 |
| 1997 | 112 | 10 | 122 |
| 1998 | 130 | 9 | 139 |
| 1999 | 131 | 9 | 140 |
| 2000 | 130 | 22 | 152 |
| 2001 | 103 | 32 | 135 |
| 2002 | 108 | 19 | 127 |
| 2003 | 108 | 23 | 131 |
| 2004 | 109 | 19 | 128 |
| 2005 | 124 | 19 | 143 |
| 2006 | 128 | 31 | 159 |
| 2007 | 129 | 23 | 152 |
| 2008 | 122 | 35 | 157 |
| 2009 | 140 | 33 | 173 |
| 2010 | 153 | 32 | 185 |
| 2011 | 132 | 41 | 173 |
| 2012 | 167 | 39 | 206 |
| 2013 | 161 | 31 | 192 |
| 2014 | 141 | 34 | 175 |
| 2015 | 129 | 28 | 157 |
| 2016 | 110 | 23 | 133 |
| 2017 | 91 | 45 | 136 |
| 2018 | 107 | 29 | 136 |
| 2019 | 89 | 41 | 130 |
| 2020 | 95 | 43 | 138 |
| 2021 | 95 | 23 | 118 |
| 2022 | 90 | 6 | 96 |
| 2023 | 4 | 0 | 4 |
Below are the most recent publications written about "HIV-1" by people in Profiles.
-
Brief Report: Dapivirine Ring HIV-1 Prevention Effectiveness for Women Engaged in Vaginal and Anal Intercourse: Insights From Mathematical Modeling. J Acquir Immune Defic Syndr. 2023 Feb 01; 92(2):122-126.
-
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 Feb 01; 92(2):153-161.
-
Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe. 2023 Jan 11; 31(1):83-96.e5.
-
Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. J Int AIDS Soc. 2023 Jan; 26(1):e26052.
-
Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors. Proc Natl Acad Sci U S A. 2023 Jan 03; 120(1):e2217883120.
-
High concordance in plasma and CSF HIV-1 drug resistance mutations despite high cases of CSF viral escape in individuals with HIV-associated cryptococcal meningitis in Botswana. J Antimicrob Chemother. 2022 Dec 23; 78(1):180-184.
-
Cooperation between cGAS and RIG-I sensing pathways enables improved innate recognition of HIV-1 by myeloid dendritic cells in elite controllers. Front Immunol. 2022; 13:1017164.
-
Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection. J Virol. 2022 12 21; 96(24):e0127022.
-
Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance. Microbiol Spectr. 2022 12 21; 10(6):e0345422.
-
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)? Clin Infect Dis. 2022 11 21; 75(Suppl 4):S530-S540.